grepcent public filings, reorganized for comparison

Aveanna Healthcare Holdings, Inc. (AVAH)

CIK: 0001832332. SIC: 8082 Services-Home Health Care Services. Latest 10-K as of: 2026-03-19.

SIC breadcrumb: Services > SIC Major Group 80 > SIC 8082 Services-Home Health Care Services

SEC company page: https://www.sec.gov/edgar/browse/?CIK=1832332. Latest filing source: 0001193125-26-115851.

Informational only. Descriptive public-record data — not a rating, forecast, or investment advice. See Disclaimer.

At a glance

FY2025 · period end 2026-01-03 · filed 2026-03-19 · accession 0001193125-26-115851 · source: SEC companyfacts

Revenue
2,433,199,000 USD verified
Net income
225,034,000 USD verified
Assets
2,012,379,000 USD verified
Net margin
9.25% computed
Operating margin
10.54% computed
Revenue YoY
+20.19% computed
ROE
115.72% computed

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

Peer & cluster context

Peer percentile fingerprint

AVAH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.AVAH ratios vs SIC peers. Source: grepcent computed from latest SEC companyfacts ratios; peer set SIC major-group 80; per-ratio N printed.RatioAVAHPeer medianPercentileNNet margin9.2%3.2%8956Operating margin10.5%5.5%7251Revenue growth20.2%11.8%7057ROE115.7%7.9%10053ROA11.2%2.8%9358Liabilities / equity9.341.139454Current ratio1.321.633558

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

Selected Fundamentals

MetricValueUnitFYFiled
Revenue2,433,199,000USD20252026-03-19
Net income225,034,000USD20252026-03-19
Assets2,012,379,000USD20252026-03-19

Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-19. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001832332.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

Download these verified figures (annual + quarterly, with per-value filing provenance): JSON · CSV

Flow metrics use full-year FY periods from 10-K/10-K/A filings; balance-sheet metrics use FY-end instants. Free cash flow = operating cash flow - capital expenditures. Missing metrics are omitted rather than fabricated.

Metric20182019202020212022202320242025
Revenue1,384,065,0001,495,105,0001,678,618,0001,787,645,0001,895,209,0002,024,506,0002,433,199,000
Net income-76,516,000-57,050,000-117,044,000-662,034,000-134,524,000-10,929,000225,034,000
Operating income38,954,000-3,487,000-36,111,000-642,276,0008,072,000139,787,000256,463,000
Gross profit419,251,000454,515,000542,404,000553,227,000595,432,000635,542,000810,481,000
Diluted EPS-0.69-3.57-0.71-0.061.05
Operating cash flow-8,714,000116,618,000-11,350,000-48,402,00022,672,00032,637,000125,857,000
Assets1,844,016,0002,334,371,0001,711,760,0001,612,985,0001,663,394,0002,012,379,000
Liabilities1,576,847,0001,696,420,0001,715,935,0001,740,420,0001,785,484,0001,817,188,000
Stockholders' equity344,993,000270,192,000265,034,000635,816,000-6,310,000-129,570,000-123,551,000194,461,000
Cash and cash equivalents137,345,00030,490,00019,217,00043,942,00084,288,000193,260,000

Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

Metric20182019202020212022202320242025
Net margin-5.53%-3.82%-6.97%-37.03%-7.10%-0.54%9.25%
Operating margin2.81%-0.23%-2.15%-35.93%0.43%6.90%10.54%
Return on equity-28.32%-21.53%-18.41%115.72%
Return on assets-3.09%-5.01%-38.68%-8.34%-0.66%11.18%
Liabilities / equity5.952.679.34
Current ratio1.310.810.830.890.981.32

Industry Peer Context

Each number-line places AVAH against the min, median, and max of latest reported values among companies in the same SIC industry when at least three peers report that ratio.

Net margin peer context

AVAH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.AVAH Net margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.6 SIC peersMin -2.2%Median 5.2%Max 10.5%AVAH 9.2%

Operating margin peer context

AVAH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.AVAH Operating margin versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.6 SIC peersMin 2.3%Median 7.9%Max 13.4%AVAH 10.5%

ROE peer context

AVAH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.AVAH ROE versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.6 SIC peersMin -4.7%Median 12.9%Max 115.7%AVAH 115.7%

ROA peer context

AVAH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.AVAH ROA versus SIC peer range. Source: grepcent computed from latest SEC companyfacts ratios for SIC industry 8082; peer count 6.6 SIC peersMin -1.6%Median 6.3%Max 17.2%AVAH 11.2%

Financial Bridges

Waterfall figures reconcile reported SEC companyfacts components. Missing bridges are omitted when required components are not present for the same fiscal year.

Income statement bridge from reported figures

AVAH FY2025 income statement bridge from reported figures.AVAH FY2025 income statement bridge from reported figures.AVAH income bridgeFY2025: revenue to net incomeSource: SEC companyfacts FY2025.Income statement bridgeReported amount$0.0B$2.0B$4.0B$2.4BRevenue-$1.6BCost$810.5MGross-$554.0MOpEx$256.5MOperating-$31.4MOther/tax$225.0MNet income

Figure provenance: SEC companyfacts FY 2025. Revenue: accession 0001193125-26-115851; concept RevenueFromContractWithCustomerExcludingAssessedTax; source concepts us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax | Gross profit: accession 0001193125-26-115851; concept GrossProfit; source concepts us-gaap:GrossProfit | Operating income: accession 0001193125-26-115851; concept OperatingIncomeLoss; source concepts us-gaap:OperatingIncomeLoss | Net income: accession 0001193125-26-115851; concept NetIncomeLoss; source concepts us-gaap:NetIncomeLoss

Financial Charts

AVAH revenue, last 5 periods. Source: SEC companyfacts FY2025.AVAH revenue, last 5 periods. Source: SEC companyfacts FY2025.AVAH RevenueLatest point: FY2025 = $2.4BSource: SEC companyfacts FY2025.Fiscal yearReported revenue$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

AVAH net income, last 5 periods. Source: SEC companyfacts FY2025.AVAH net income, last 5 periods. Source: SEC companyfacts FY2025.AVAH Net incomeLatest point: FY2025 = $225.0MSource: SEC companyfacts FY2025.Fiscal yearNet income-$750.0M$0.0B$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

AVAH operating income, last 5 periods. Source: SEC companyfacts FY2025.AVAH operating income, last 5 periods. Source: SEC companyfacts FY2025.AVAH Operating incomeLatest point: FY2025 = $256.5MSource: SEC companyfacts FY2025.Fiscal yearOperating income-$750.0M$0.0B$500.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: OperatingIncomeLoss. Source concepts: us-gaap:OperatingIncomeLoss.

AVAH gross profit, last 5 periods. Source: SEC companyfacts FY2025.AVAH gross profit, last 5 periods. Source: SEC companyfacts FY2025.AVAH Gross profitLatest point: FY2025 = $810.5MSource: SEC companyfacts FY2025.Fiscal yearGross profit$0.0B$500.0M$1.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: GrossProfit. Source concepts: us-gaap:GrossProfit.

AVAH diluted eps, last 5 periods. Source: SEC companyfacts FY2025.AVAH diluted eps, last 5 periods. Source: SEC companyfacts FY2025.AVAH Diluted EPSLatest point: FY2025 = $1.05/shareSource: SEC companyfacts FY2025.Fiscal yearDiluted EPS (USD/share)-$4.00/share$0.00/share$2.00/shareFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

AVAH operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.AVAH operating cash flow, last 5 periods. Source: SEC companyfacts FY2025.AVAH Operating cash flowLatest point: FY2025 = $125.9MSource: SEC companyfacts FY2025.Fiscal yearOperating cash flow-$250.0M$0.0B$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: NetCashProvidedByUsedInOperatingActivities. Source concepts: us-gaap:NetCashProvidedByUsedInOperatingActivities.

AVAH assets, last 5 periods. Source: SEC companyfacts FY2025.AVAH assets, last 5 periods. Source: SEC companyfacts FY2025.AVAH AssetsLatest point: FY2025 = $2.0BSource: SEC companyfacts FY2025.Fiscal yearAssets$0.0B$2.0B$4.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: Assets. Source concepts: us-gaap:Assets.

AVAH liabilities, last 5 periods. Source: SEC companyfacts FY2025.AVAH liabilities, last 5 periods. Source: SEC companyfacts FY2025.AVAH LiabilitiesLatest point: FY2025 = $1.8BSource: SEC companyfacts FY2025.Fiscal yearLiabilities$0.0B$1.0B$2.0BFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: Liabilities. Source concepts: us-gaap:Liabilities.

AVAH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.AVAH stockholders' equity, last 5 periods. Source: SEC companyfacts FY2025.AVAH Stockholders' equityLatest point: FY2025 = $194.5MSource: SEC companyfacts FY2025.Fiscal yearStockholders' equity-$250.0M$0.0B$750.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: StockholdersEquity. Source concepts: us-gaap:StockholdersEquity.

AVAH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.AVAH cash and cash equivalents, last 5 periods. Source: SEC companyfacts FY2025.AVAH Cash and cash equivalentsLatest point: FY2025 = $193.3MSource: SEC companyfacts FY2025.Fiscal yearCash and cash equivalents$0.0B$125.0M$250.0MFY2021FY2022FY2023FY2024FY2025

Figure provenance: SEC companyfacts. Latest point: FY 2025 ended 2026-01-03; accession 0001193125-26-115851; filed 2026-03-19. Concept: CashAndCashEquivalentsAtCarryingValue. Source concepts: us-gaap:CashAndCashEquivalentsAtCarryingValue.

As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.

Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-13. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001832332.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

QuarterEnd DateRevenueNet IncomeDiluted EPSMethod
2022-Q32022-10-010.13reported discrete quarter
2023-Q12023-04-01-0.17reported discrete quarter
2023-Q22023-07-01471,945,00025,599,0000.13reported discrete quarter
2023-Q32023-09-30478,010,000-102,389,000-0.54reported discrete quarter
2023-Q42023-12-30478,841,000-25,736,000derived Q4 = FY annual - nine-month YTD
2024-Q12024-03-30490,653,000-11,172,000-0.06reported discrete quarter
2024-Q22024-06-29504,958,00013,906,0000.07reported discrete quarter
2024-Q32024-09-28509,023,000-42,843,000-0.22reported discrete quarter
2024-Q42024-12-28519,872,00029,180,000derived Q4 = FY annual - nine-month YTD
2025-Q12025-03-29559,224,0005,193,0000.03reported discrete quarter
2025-Q22025-06-28589,553,00027,025,0000.13reported discrete quarter
2025-Q32025-09-27621,942,00014,064,0000.06reported discrete quarter
2026-Q12026-04-04647,915,00041,653,0000.19reported discrete quarter
2026-Q22026-07-04670,483,00040,293,0000.18reported discrete quarter

Quarterly Charts

AVAH quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH quarterly revenue, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH Quarterly RevenueLatest point: 2026-Q2 = $670.5MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Revenue$0.0B$375.0M$750.0M2023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-07-04; accession 0001193125-26-347842; filed 2026-08-13. Concept: RevenueFromContractWithCustomerExcludingAssessedTax. Source concepts: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

AVAH quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH quarterly net income, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH Quarterly Net incomeLatest point: 2026-Q2 = $40.3MSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Net income-$250.0M$0.0B$250.0M2023-Q22023-Q32023-Q42024-Q12024-Q22024-Q32024-Q42025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-07-04; accession 0001193125-26-347842; filed 2026-08-13. Concept: NetIncomeLoss. Source concepts: us-gaap:NetIncomeLoss.

AVAH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH quarterly diluted eps, last 12 periods. Source: SEC companyfacts 2026-Q2.AVAH Quarterly Diluted EPSLatest point: 2026-Q2 = $0.18/shareSource: SEC companyfacts 2026-Q2.Fiscal quarterQuarterly Diluted EPS (USD/share)-$1.00/share$0.00/share$0.50/share2022-Q32023-Q12023-Q22023-Q32024-Q12024-Q22024-Q32025-Q12025-Q22025-Q32026-Q12026-Q2

Figure provenance: SEC companyfacts. Latest point: FY 2026 ended 2026-07-04; accession 0001193125-26-347842; filed 2026-08-13. Concept: EarningsPerShareDiluted. Source concepts: us-gaap:EarningsPerShareDiluted.

Business

Read AVAH's verbatim Item 1 Business section from its latest 10-K: Business.

Risk Factors

Read AVAH's verbatim Item 1A Risk Factors from its latest 10-K: Risk Factors.

Latest quarter (10-Q)

Latest 10-Q source: 0001193125-26-347842.

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture. Confidence: high. Filing date: 2026-08-13. Report date: 2026-07-04.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis provides information we believe is relevant to an assessment and understanding of our results of operations, financial condition, liquidity and cash flows for the periods presented below. This discussion should be read in conjunction with the interim unaudited consolidated financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q and in conjunction with the audited consolidated financial statements and related notes, our “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in each case included in our Annual Report on Form 10-K for the fiscal year ended January 3, 2026 filed with the SEC. As discussed in the section above titled “Cautionary Note Regarding Forward-Looking Statements,” the following discussion contains forward-looking statements that are based upon our current expectations, including with respect to our future revenues and operating results. Our actual results may differ materially from those anticipated in such forward-looking statements as a result of various factors. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended January 3, 2026.

Unless otherwise provided, “Aveanna,” “we,” “our” and the “Company” refer to Aveanna Healthcare Holdings Inc. and its consolidated subsidiaries.

Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52-week or 53-week fiscal year. “Fiscal year 2026” refers to the 52-week fiscal year ending on January 2, 2027. “Fiscal year 2025” refers to the 53-week fiscal year ended on January 3, 2026. The “three-month period ended July 4, 2026”, or “second quarter of 2026” refers to the 13-week fiscal quarter ended on July 4, 2026. The “three-month period ended June 28, 2025” or “second quarter of 2025” refers to the 13-week fiscal quarter ended on June 28, 2025. The "six-month period ended July 4, 2026", or "first six months of 2026", refers to the period from January 4, 2026 through July 4, 2026. The "six-month period ended June 28, 2025", or "first six months of 2025", refers to the period from December 29, 2024 through June 28, 2025.

Overview

We are a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations. We directly address the most pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home, the lower cost care setting preferred by patients. Our patient-centered care delivery platform is designed to improve the quality of care our patients receive, which allows them to remain in their homes and minimizes the overutilization of high-cost care settings such as hospitals. Our clinical model is led by our caregivers, primarily skilled nurses, who provide specialized care to address the complex needs of each patient we serve across the full range of patient populations: newborns, children, adults and seniors. We have invested significantly in our platform to bring together best-in-class talent at all levels of the organization and support such talent with industry leading training, clinical programs, infrastructure and technology-enabled systems, which are increasingly essential in an evolving healthcare industry. We believe our platform creates sustainable competitive advantages that support our ability to continue driving rapid growth, both organically and through acquisitions, and positions us as the partner of choice for the patients we serve.

Segments

We deliver our services to patients through three segments: Private Duty Services (“PDS”); Home Health & Hospice (“HHH”); and Medical Solutions (“MS”).

The following table summarizes the revenues generated by each of our segments for the three-month periods ended July 4, 2026 and June 28, 2025, respectively:

(dollars in thousands)ConsolidatedPDSHHHMS
For the three-month period ended July 4, 2026$670,483$553,929$69,023$47,531
Percentage of consolidated revenue83%10%7%
For the three-month period ended June 28, 2025$589,553$486,012$60,112$43,429
Percentage of consolidated revenue83%10%7%

The following table summarizes the revenues generated by each of our segments for the six-month periods ended July 4, 2026 and June 28, 2025, respectively:

(dollars in thousands)ConsolidatedPDSHHHMS
For the six-month period ended July 4, 2026$1,318,398$1,089,581$135,632$93,185
Percentage of consolidated revenue83%10%7%
For the six-month period ended June 28, 2025$1,148,777$946,010$116,845$85,922
Percentage of consolidated revenue82%10%8%

19

PDS Segment

Private Duty Services predominantly includes private duty nursing services (“PDN Services”), as well as pediatric therapy services (“Therapy Services”). PDN Services patients typically enter our service as children, as our most significant referral sources for new patients are children’s hospitals. It is common for PDN Services patients to continue to receive our services into adulthood, as approximately 30% of our PDN Services patients are over the age of 18.

PDN Services involve the provision of clinical and non-clinical hourly care to patients in their homes, which is the preferred setting for patient care. PDN Services typically last four to 24 hours a day, provided by our registered nurses, licensed practical nurses, home health aides, and other non-clinical caregivers who are focused on providing high-quality short-term and long-term clinical care to medically complex children and adults with a wide variety of serious illnesses and conditions. Patients who typically qualify for PDN Services include those with the following conditions:


Tracheotomies or ventilator dependence;


Dependence on continuous nutritional feeding through a “G-tube” or “NG-tube”;


Dependence on intravenous nutrition;


Oxygen-dependence in conjunction with other medical needs; and


Complex medical needs such as frequent seizures.

PDN Services include:


In-home skilled nursing services to medically complex children and adults;


Nursing services in school settings in which our caregivers accompany patients to school;


Services to patients in our Pediatric Day Healthcare Centers (“PDHC”); and


Non-clinical care, including programs such as support services and personal care services.

Therapy Services provide a valuable multidisciplinary approach that we believe serves all of a child’s therapy needs. We provide both in-clinic and home-based therapy services to our patients. Therapy Services include physical, occupational and speech services. We regularly collaborate with physicians and other community healthcare providers, which allows us to provide more comprehensive care.

HHH Segment

Our Home Health and Hospice segment predominantly includes home health services (“HH Services”), as well as hospice and specialty program services. Our HHH patients typically enter our service as seniors, and our most significant referral sources for new patients are hospitals, physicians and long-term care facilities.

HH Services involve the provision of in-home services to our patients by our clinicians, which may include nurses, therapists, social workers and home health aides. Our caregivers work with our patients’ physicians to deliver a personalized plan of care to our patients in their homes. Home healthcare can help our patients recover after a hospitalization or surgery and assist patients in managing chronic illnesses. We also help our patients manage their medications. Through our care, we help our patients recover more fully in the comfort of their own homes, while remaining as independent as possible. HH Services include: in-home skilled nursing services; physical, occupational and speech therapy; medical social services and aide services.

Our hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Our hospice care is a positive, empowering form of care designed to provide comfort and support to our patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The goal of hospice is to neither prolong life nor hasten death, but to help our patients live as dignified and pain-free as possible. Our hospice care is provided by a team of specially trained professionals in a variety of living situations, including at home, at the hospital, a nursing home, or an assisted living facility.

MS Segment

Through our Medical Solutions segment, we offer a comprehensive line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. We provide our patients with access to one of the largest selections of enteral formulas, supplies and pumps in our industry, with more than 300 nutritional formulas available. Our registered nurses, registered dietitians and customer service technicians support our patients 24 hours per day, 365 days per year, in-hospital, at-home, or remotely to help ensure that our patients have the best nutrition assessments, change order reviews and formula selection expertise.

20

Recent Developments

Acquisition of Family First Homecare

On June 1, 2026, the Company completed the acquisition of Family First Holding, LLC, a scaled, multi-state provider of pediatric home care that primarily provides skilled Private Duty Nursing services with 27 locations in seven states including Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas, and North Carolina. The Company paid $173.7 million in cash as consideration, after customary adjustments for working capital and other items, funded with cash on hand. The operating results of Family First Holding, LLC subsequent to the acquisition date are included in our PDS operating segment.

Important Operating Metrics

We review the following important metrics on a segment basis and not on a consolidated basis:

PDS and MS Segment Operating Metrics

Volume

Volume represents PDS hours of care provided and MS unique patients served, which is how we measure the amount of our patient services provided. We review the number of hours of PDS care provided on a weekly basis and the number of MS unique patients served on a weekly basis. We believe volume is an important metric because it helps us understand how the Company is growing in each of these segments through strategic planning and acquisitions. We also use this metric to inform strategic decision making in determining opportunities for growth.

Revenue Rate

For our PDS and MS segments, revenue rate is calculated as revenue divided by PDS hours of care provided or the number of MS unique patients served, respectively. We believe revenue rate is an important metric because it represents the amount of revenue we receive per PDS hour of patient service or per individual MS patient transaction and helps management assess the amount of fees that we are able to bill for our services. Management uses this metric to assess how effectively we optimize reimbursement rates.

Cost of Revenue Rate

For our PDS and MS segments, cost of revenue rate is calculated as cost of revenue divided by PDS hours of care provided or the number of MS unique patients served, respectively. We believe cost of revenue rate is an important metric because it helps

[Excerpt truncated for page length; source filing is linked above.]

Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: 0001193125-26-115851. The complete FY 2026 MD&A is published at /company/AVAH/mda/fy2026/.

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Confidence: high. Filing date: 2026-03-19. Report date: 2026-01-03.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Annual Report on Form 10-K contains forward-looking statements within the meaning of the PSLRA, Section 27A of the Securities Act, and Section 21E of the Exchange Act, about our expectations, beliefs, plans and intentions regarding our product development efforts, business, financial condition, results of operations, strategies and prospects. You can identify forward-looking statements by the fact that these statements do not relate to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those contained in “Item 1A — Risk Factors” of this Annual Report on Form 10-K. Forward-looking statements reflect our views only as of the date they are made. We do not undertake any obligation to update forward-looking statements except as required by applicable law. We intend that all forward-looking statements be subject to the safe harbor provisions of PSLRA.

Our fiscal year ends on the Saturday that is closest to December 31 of a given year, resulting in either a 52-week or 53-week fiscal year. Our “fiscal year 2025” refers to the 53-week fiscal year ended on January 3, 2026. Our “fiscal year 2024” refers to the 52-week fiscal year ended on December 28, 2024. Our “fiscal year 2023” refers to the 52-week fiscal year ended on December 30, 2023.

Overview

We are a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations. We directly address the most pressing challenges facing the U.S. healthcare system by providing safe, high-quality care in the home, the lower cost care setting preferred by patients. Our patient-centered care delivery platform is designed to improve the quality of care our patients receive, which allows them to remain in their homes and minimizes the overutilization of high-cost care settings such as hospitals. Our clinical model is led by our caregivers, primarily skilled nurses, who provide specialized care to address the complex needs of each patient we serve across the full range of patient populations: newborns, children, adults and seniors. We have invested significantly in our platform to bring together best-in-class talent at all levels of the organization and support such talent with industry leading training, clinical programs, infrastructure and technology-enabled systems, which are increasingly essential in an evolving healthcare industry. We believe our platform creates sustainable competitive advantages that support our ability to continue driving rapid growth, both organically and through acquisitions, and positions us as the partner of choice for the patients we serve.

51

Segments

We deliver our services to patients through three segments: Private Duty Services (“PDS”); Home Health & Hospice (“HHH”); and Medical Solutions (“MS”).

The following table summarizes the revenues generated by each of our segments for the fiscal years ended January 3, 2026 and December 28, 2024:

(dollars in thousands)ConsolidatedPDSHHHMS
For the fiscal year ended January 3, 2026$2,433,199$2,001,147$248,557$183,495
Percentage of consolidated revenue82%10%8%
For the fiscal year ended December 28, 2024$2,024,506$1,634,609$217,805$172,092
Percentage of consolidated revenue81%11%8%

PDS Segment

Private Duty Services predominantly includes private duty nursing services (“PDN Services”), as well as pediatric therapy services (“Therapy Services”). PDN Services patients typically enter our service as children, as our most significant referral sources for new patients are children’s hospitals. It is common for PDN Services patients to continue to receive our services into adulthood, as approximately 30% of our PDN Services patients are over the age of 18.

PDN Services involve the provision of clinical and non-clinical hourly care to patients in their homes, which is the preferred setting for patient care. PDN Services typically last four to 24 hours a day, provided by our registered nurses, licensed practical nurses, home health aides, and other non-clinical caregivers who are focused on providing high-quality short-term and long-term clinical care to medically complex children and adults with a wide variety of serious illnesses and conditions. Patients who typically qualify for PDN Services include those with the following conditions:


Tracheotomies or ventilator dependence;


Dependence on continuous nutritional feeding through a “G-tube” or “NG-tube”;


Dependence on intravenous nutrition;


Oxygen-dependence in conjunction with other medical needs; and


Complex medical needs such as frequent seizures.

PDN Services include:


In-home skilled nursing services to medically complex children and adults;


Nursing services in school settings in which our caregivers accompany patients to school;


Services to patients in our Pediatric Day Healthcare Centers (“PDHC”); and


Non-clinical care, including programs such as support services and personal care services.

Therapy Services provide a valuable multidisciplinary approach that we believe serves all of a child’s therapy needs. We provide both in-clinic and home-based therapy services to our patients. Therapy Services include physical, occupational and speech services. We regularly collaborate with physicians and other community healthcare providers, which allows us to provide more comprehensive care.

HHH Segment

Our Home Health and Hospice segment predominantly includes home health services (“HH Services”), as well as hospice and specialty program services. Our HHH patients typically enter our service as seniors, and our most significant referral sources for new patients are hospitals, physicians and long-term care facilities.

HH Services involve the provision of in-home services to our patients by our clinicians, which may include nurses, therapists, social workers and home health aides. Our caregivers work with our patients’ physicians to deliver a personalized plan of care to our patients in their homes. Home healthcare can help our patients recover after a hospitalization or surgery and assist patients in managing chronic illnesses. We also help our patients manage their medications. Through our care, we help our patients recover more fully in the comfort of their own homes, while remaining as independent as possible. HH Services include: in-home skilled nursing services; physical, occupational and speech therapy; medical social services and aide services.

52

Our hospice services involve a supportive philosophy and concept of care for those nearing the end of life. Our hospice care is a positive, empowering form of care designed to provide comfort and support to our patients and their families when a life-limiting illness no longer responds to cure-oriented treatments. The goal of hospice is to neither prolong life nor hasten death, but to help our patients live as dignified and pain-free as possible. Our hospice care is provided by a team of specially trained professionals in a variety of living situations, including at home, at the hospital, a nursing home, or an assisted living facility.

MS Segment

Through our Medical Solutions segment, we offer a comprehensive line of enteral nutrition supplies and other products to adults and children, delivered on a periodic or as-needed basis. We provide our patients with access to a large selection of enteral formulas, supplies and pumps in our industry, with more than 300 nutritional formulas available. Our registered nurses, registered dietitians and customer service technicians support our patients 24 hours per day, 365 days per year, in-hospital, at-home, or remotely to help ensure that our patients have the best nutrition assessments, change order reviews and formula selection expertise.

Recent Developments

Regulatory Developments

On June 30, 2025, the Centers for Medicare & Medicaid Services (“CMS”) issued its calendar year 2026 (“CY 2026”) proposed rule for the home health prospective payment system. CMS estimates the proposed rule would reduce home health payments by 6.4% in CY 2026 relative to 2025. On November 28, 2025, CMS released the final rule which reduced Medicare reimbursement rates by 1.3%. This update includes a 3.2% market basket update, reduced by a 0.8% cut for productivity. Future changes in CMS reimbursement methodology, or future decreases in reimbursement rates could have a material adverse effect on our business, financial condition, results of operations, and cash flows.

On July 4, 2025, H.R. 1, also known as the One Big Beautiful Bill Act (“OBBBA”), was enacted into law. The Congressional Budget Office projects OBBBA will result in a reduction to federal Medicaid spending by an estimated $1.15 trillion over the next ten years. The changes to Medicaid made by OBBBA include provisions expected to reduce the population of Medicaid recipients through more stringent eligibility requirements, reductions in provider taxes, work (community engagement) requirements, limits on state-directed payments, and other changes. Most of the applicable provisions have implementation dates of December 31, 2026, or later. While there were no specific changes to the Medicaid waiver programs that a majority of our patient population qualifies for services under and no provisions that we believe directly impact the reimbursement rates of the services we provide, the resulting reductions to state Medicaid budgets may indirectly impact future rate expansion for certain Medicaid-funded services.

Agreement to Acquire Family First Homecare

On March 12, 2026, the Company announced that it had entered into a definitive agreement to acquire Family First Holding, LLC, a scaled, multi-state provider of pediatric home care that primarily provides skilled Private Duty Nursing services with 27 locations in seven states including Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas, and North Carolina, where it is currently launching operations. The purchase price for the acquisition is $175.5 million in cash, subject to customary adjustments. The transaction is expected to close in the second fiscal quarter of 2026, subject to, among other things, customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. We intend to fund the acquisition with a combination of cash on hand and borrowings under our Securitization Facility.

Important Operating Metrics

We review the following important metrics on a segment basis and not on a consolidated basis:

PDS Segment and MS Segment Operating Metrics

Volume

Volume represents PDS hours of care provided and MS unique patients served, which is how we measure the amount of our patient services provided. We review the number of hours of PDS care provided on a weekly basis and the number of MS unique patients served on a weekly basis. We believe volume is an important metric because it helps us understand how the Company is growing in each of

53

these segments through strategic planning and acquisitions. We also use this metric to inform strategic decision making in determining opportunities for growth.

Revenue

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2026 MD&A or browse all MD&A years.

MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

Macro cross-references for AVAH

Indicators mapped to this company's SIC classification (industry 8082 Services-Home Health Care Services) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

Macro-to-micro threads including this sector: US labor market, Growth & output, Government finances, Sector employment.

All 71 macro indicators →

For LLMs & downloads

Markdown twin: /company/AVAH.md · JSON record: /company/AVAH.json · verified financials: JSON / CSV · machine TOC for the whole site: /llms.txt